<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31742901</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.</ArticleTitle><Pagination><StartPage>2489</StartPage><EndPage>2502</EndPage><MedlinePgn>2489-2502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.50943</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the diagnostic and prognostic significance of neurofilament light chain (NfL), TAR DNA-binding protein 43 (TDP-43), and total tau (t-tau) in cerebrospinal fluid (CSF) and plasma of patients with amyotrophic lateral sclerosis (ALS) and to investigate whether the combined use of those biomarker candidates can improve their diagnostic performance.</AbstractText><AbstractText Label="METHODS">This was a single-center, prospective, longitudinal study. CSF and plasma samples were collected at the time of enrollment from a discovery cohort of 29 patients with ALS and 29 age-matched controls without neurodegenerative disease. In a validation cohort, there were 46 patients with ALS, and 46 control (not age-matched) patients with motor weakness resulting from neuromuscular diseases. NfL, TDP-43, and t-tau levels in CSF and plasma were measured using ultrasensitive single molecule assay (Simoa) technology.</AbstractText><AbstractText Label="RESULTS">The following findings were reproducibly observed among the discovery and validation cohorts: increased levels of CSF NfL, plasma NfL, and CSF TDP-43 in ALS compared with control groups; shorter survival associated with higher levels of CSF and plasma NfL. When the CSF NfL and CSF TDP-43 levels were combined, the areas under the ROC curves (AUC) were slightly improved relative to AUCs for each biomarker alone.</AbstractText><AbstractText Label="INTERPRETATION">CSF and plasma NfL may not only serve as diagnostic biomarkers but also provide a measure of disease progression. CSF TDP-43 is also useful as a diagnostic biomarker of ALS, but has no prognostic value. The combined use of CSF NfL and CSF TDP-43 may be a useful biomarker for the diagnosis of ALS.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasai</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6424-0738</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmichi</LastName><ForeName>Takuma</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatebe</LastName><ForeName>Harutsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Innovation and Translational Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noto</LastName><ForeName>Yu-Ichi</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitani-Morii</LastName><ForeName>Fukiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinomoto</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allsop</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>15K09319</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology</Agency><Country>International</Country></Grant><Grant><GrantID>18K07506</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology</Agency><Country>International</Country></Grant><Grant><GrantID>18K15461</GrantID><Agency>Ministry of Education, Culture, Sports, Science and Technology</Agency><Country>International</Country></Grant><Grant><GrantID>18dk0207030h0003</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country>International</Country></Grant><Grant><GrantID>19ek0109222h0003</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no competing financial interests. Also, no nonfinancial conflicts of interest exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31742901</ArticleId><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="doi">10.1002/acn3.50943</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 2017;74:525&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. Fluid&#x2010;based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics 2017;14:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Kuiperij HB, van Blitterswijk MM, et al. TDP&#x2010;43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:446&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">22873561</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A, D'Errico E. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Deuschle C, Rattay TW, et al. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging 2015;36:1072&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">25453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:442&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Spotorno N, Schreiber F, et al. Significance of CSF NfL and tau in ALS. J Neurol 2018;265:2633&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Tokuda T, Ishigami N, et al. Increased TDP&#x2010;43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009;117:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y, Shibuya K, Sato Y, et al. Elevated CSF TDP&#x2010;43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler 2011;12:140&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">21126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 2015;22:215&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750431</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Shen D, Tai H, Cui L. Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta&#x2010;analysis. Front Aging Neurosci 2016;8:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126108</ArticleId><ArticleId IdType="pubmed">27965574</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol 2019;45:291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Hendrich C, Sperfeld AD, et al. TDP&#x2010;43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008;65:1481&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Arai T, Yamashita M, et al. Differential diagnosis of amyotrophic lateral sclerosis from Guillain&#x2010;Barre syndrome by quantitative determination of TDP&#x2010;43 in cerebrospinal fluid. Int J Neurosci 2014;124:344&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">24066851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal fluid TAR DNA&#x2010;binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord 2017;44:144&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">28848086</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, et al. TDP&#x2010;43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. BMC Neurol 2018;18:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds PG, Davidson Y, Mishra M, et al. Plasma phosphorylated&#x2010;TDP&#x2010;43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol 2009;118:647&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809136</ArticleId><ArticleId IdType="pubmed">19823856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, et al. Single&#x2010;molecule enzyme&#x2010;linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez&#x2010;Jimenez FJ, Hernanz A, Medina&#x2010;Acebron S, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005;111:114&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15644071</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P, Valentino F, Piccoli T, et al. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol 2009;16:257&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;28:852&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>